Dual GIP/GLP-1 Receptor Agonist | Subcutaneous Injection | Once Weekly

Tirzepatide takes weight loss medication to the next level. While semaglutide targets one hormone receptor (GLP-1), tirzepatide is a dual agonist — meaning it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual action may offer enhanced appetite suppression, improved blood sugar control, and greater weight loss compared to GLP-1-only medications.

How it works: By targeting both GLP-1 and GIP receptors, tirzepatide amplifies the body’s natural signals for fullness and metabolic regulation. Research suggests this dual mechanism leads to greater reductions in appetite, more efficient fat burning, and improved insulin sensitivity compared to single-receptor medications.

What the research shows:



In the SURMOUNT-1 trial, participants without diabetes taking the highest dose of tirzepatide (15 mg) lost an average of approximately 22.5% of their body weight over 72 weeks.



Between 89% and 91% of participants on the 10 mg or 15 mg doses achieved at least 5% weight loss, and 50-57% lost 20% or more.



Head-to-head comparison data from the SURMOUNT-5 trial showed tirzepatide achieving roughly 20% weight loss at 72 weeks, compared to about 14% with semaglutide — demonstrating a meaningful edge in weight reduction.



In addition to weight loss, tirzepatide has shown improvements in blood pressure, cholesterol, blood sugar control, and waist circumference.



More than 95% of participants with prediabetes who received tirzepatide converted to normal blood sugar levels by the end of the primary study period.